Two medicines, side by side
Carvedilol vs nebivolol
Carvedilol and nebivolol are both labeled for high blood pressure. Drugs@FDA records approvals of carvedilol since 1995 and of nebivolol since 2007. Pharmacies paid $0.0179 per carvedilol 6.25 mg tablet and $0.141 per nebivolol 10 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, carvedilol is an alpha-adrenergic blocker and nebivolol a beta-adrenergic blocker.
Check it at the source: the carvedilol FDA label on DailyMed (effective July 31, 2026); the nebivolol FDA label on DailyMed (effective August 1, 2024).
Highlights of the carvedilol record
Carvedilol (Coreg) · label of July 31, 2026
Used for
From the label: indicationsINDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]
On the market
- Earliest approval on file
- September 14, 1995
- Generic labelers
- 41 labelers
- Pharmacy cost
- $0.0179 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 22
Highlights of the nebivolol record
Nebivolol (Bystolic) · label of August 1, 2024
Used for
From the label: indicationsINDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension BYSTOLIC is indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. […]
On the market
- Earliest approval on file
- December 17, 2007
- Generic labelers
- 23 labelers
- Pharmacy cost
- $0.141 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 5
Source: FDA drug labels via openFDA (Carvedilol label of July 31, 2026, Nebivolol label of August 1, 2024); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do carvedilol and nebivolol differ on the record?
In FDA's classes, carvedilol is an alpha-adrenergic blocker and nebivolol a beta-adrenergic blocker.
How each works, in its label's words: Carvedilol, “COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers …”; Nebivolol, “The mechanism of action of the antihypertensive response of BYSTOLIC has not been definitively established.”
Half-life, in each label's words: Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”; Nebivolol, “The active isomer (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most …”
Generics: carvedilol since 2007; nebivolol since 2015 (Drugs@FDA).
| Carvedilol | Nebivolol | |
|---|---|---|
| Labeled for | Heart failure, High blood pressure | High blood pressure |
| Pharmacologic class | alpha-Adrenergic Blocker, beta-Adrenergic Blocker | beta-Adrenergic Blocker |
| How it works (label) | COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. | The mechanism of action of the antihypertensive response of BYSTOLIC has not been definitively established. |
| Half-life (label) | Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. | The active isomer (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most people), and 19 hours in poor metabolizers and exposure to d-nebivolol is substantially increased in … |
| Earliest approval on file (Drugs@FDA) | September 14, 1995 | December 17, 2007 |
| First generic approved | September 5, 2007 | April 16, 2015 |
| Generic labelers (NDC) | 41 labelers | 23 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0179 per tablet (Carvedilol 6.25 mg tablet) | $0.141 per tablet (Nebivolol 10 mg tablet) |
| 12-month price change | -4% | +0.8% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 22 | 5 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 137,029 | 33,555 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to carvedilol
- every medicine labeled for the same conditions